Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype

Ji Hyun Lee, Young Kyung Lee, Eun Kyung Kim, Tae Hyung Kim, Jin Won Huh, Woo Jin Kim, Jin Hwa Lee, Sang Min Lee, Sang Yeub Lee, Seong Yong Lim, Tae Rim Shin, Ho Il Yoon, Seung Soo Sheen, Nam Kug Kim, Joon Beom Seo, Yeon Mok Oh, Sang Do Lee

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Rationale: Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disorder in which a number of different pathological processes lead to recognition of patient subgroups that may have individual characteristics and distinct responses to treatment. Objectives: We tested the hypothesis that responses of lung function to 3 months of combined inhalation of long-acting beta-agonist and corticosteroid might differ among patients with various COPD subtypes. Methods: We classified 165 COPD patients into four subtypes according to the severity of emphysema and airflow obstruction: emphysema-dominant, obstruction-dominant, mild-mixed, and severe-mixed. The emphysema-dominant subtype was defined by an emphysema index on computed tomography of more than 20% and FEV1 more than 45% of the predicted value. The obstruction-dominant subtype had an emphysema index ≤ 20% and FEV1 ≤ 45%, the mild-mixed subtype had an emphysema index ≤ 20% and FEV1 > 45%, and the severe-mixed subtype had an emphysema index > 20% and FEV1 ≤ 45%. Patients were recruited prospectively and treated with 3 months of combined inhalation of long-acting beta-agonist and corticosteroid. Results: After 3 months of combined inhalation of long-acting beta-agonist and corticosteroid, obstruction-dominant subtype patients showed a greater FEV1 increase and more marked dyspnea improvement than did the emphysema-dominant subgroup. The mixed-subtype patients (both subgroups) also showed significant improvement in FEV1 compared with the emphysema-dominant subgroup. Emphysema-dominant subtype patients showed no improvement in FEV1 or dyspnea after the 3-month treatment period. Conclusion: The responses to 3 months of combined inhalation of long-acting beta-agonist and corticosteroid differed according to COPD subtype.

Original languageEnglish
Pages (from-to)542-549
Number of pages8
JournalRespiratory Medicine
Volume104
Issue number4
DOIs
Publication statusPublished - 2010 Apr 1

Fingerprint

Emphysema
Chronic Obstructive Pulmonary Disease
Adrenal Cortex Hormones
Inhalation
Dyspnea
Pathologic Processes
Tomography
Lung

Keywords

  • COPD
  • Corticosteroid
  • Inhaled long acting bronchodilator
  • Subtype

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Lee, J. H., Lee, Y. K., Kim, E. K., Kim, T. H., Huh, J. W., Kim, W. J., ... Lee, S. D. (2010). Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respiratory Medicine, 104(4), 542-549. https://doi.org/10.1016/j.rmed.2009.10.024

Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. / Lee, Ji Hyun; Lee, Young Kyung; Kim, Eun Kyung; Kim, Tae Hyung; Huh, Jin Won; Kim, Woo Jin; Lee, Jin Hwa; Lee, Sang Min; Lee, Sang Yeub; Lim, Seong Yong; Shin, Tae Rim; Yoon, Ho Il; Sheen, Seung Soo; Kim, Nam Kug; Seo, Joon Beom; Oh, Yeon Mok; Lee, Sang Do.

In: Respiratory Medicine, Vol. 104, No. 4, 01.04.2010, p. 542-549.

Research output: Contribution to journalArticle

Lee, JH, Lee, YK, Kim, EK, Kim, TH, Huh, JW, Kim, WJ, Lee, JH, Lee, SM, Lee, SY, Lim, SY, Shin, TR, Yoon, HI, Sheen, SS, Kim, NK, Seo, JB, Oh, YM & Lee, SD 2010, 'Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype', Respiratory Medicine, vol. 104, no. 4, pp. 542-549. https://doi.org/10.1016/j.rmed.2009.10.024
Lee, Ji Hyun ; Lee, Young Kyung ; Kim, Eun Kyung ; Kim, Tae Hyung ; Huh, Jin Won ; Kim, Woo Jin ; Lee, Jin Hwa ; Lee, Sang Min ; Lee, Sang Yeub ; Lim, Seong Yong ; Shin, Tae Rim ; Yoon, Ho Il ; Sheen, Seung Soo ; Kim, Nam Kug ; Seo, Joon Beom ; Oh, Yeon Mok ; Lee, Sang Do. / Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. In: Respiratory Medicine. 2010 ; Vol. 104, No. 4. pp. 542-549.
@article{0f7b596b1c65419f8436ed41ee8e7ec6,
title = "Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype",
abstract = "Rationale: Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disorder in which a number of different pathological processes lead to recognition of patient subgroups that may have individual characteristics and distinct responses to treatment. Objectives: We tested the hypothesis that responses of lung function to 3 months of combined inhalation of long-acting beta-agonist and corticosteroid might differ among patients with various COPD subtypes. Methods: We classified 165 COPD patients into four subtypes according to the severity of emphysema and airflow obstruction: emphysema-dominant, obstruction-dominant, mild-mixed, and severe-mixed. The emphysema-dominant subtype was defined by an emphysema index on computed tomography of more than 20{\%} and FEV1 more than 45{\%} of the predicted value. The obstruction-dominant subtype had an emphysema index ≤ 20{\%} and FEV1 ≤ 45{\%}, the mild-mixed subtype had an emphysema index ≤ 20{\%} and FEV1 > 45{\%}, and the severe-mixed subtype had an emphysema index > 20{\%} and FEV1 ≤ 45{\%}. Patients were recruited prospectively and treated with 3 months of combined inhalation of long-acting beta-agonist and corticosteroid. Results: After 3 months of combined inhalation of long-acting beta-agonist and corticosteroid, obstruction-dominant subtype patients showed a greater FEV1 increase and more marked dyspnea improvement than did the emphysema-dominant subgroup. The mixed-subtype patients (both subgroups) also showed significant improvement in FEV1 compared with the emphysema-dominant subgroup. Emphysema-dominant subtype patients showed no improvement in FEV1 or dyspnea after the 3-month treatment period. Conclusion: The responses to 3 months of combined inhalation of long-acting beta-agonist and corticosteroid differed according to COPD subtype.",
keywords = "COPD, Corticosteroid, Inhaled long acting bronchodilator, Subtype",
author = "Lee, {Ji Hyun} and Lee, {Young Kyung} and Kim, {Eun Kyung} and Kim, {Tae Hyung} and Huh, {Jin Won} and Kim, {Woo Jin} and Lee, {Jin Hwa} and Lee, {Sang Min} and Lee, {Sang Yeub} and Lim, {Seong Yong} and Shin, {Tae Rim} and Yoon, {Ho Il} and Sheen, {Seung Soo} and Kim, {Nam Kug} and Seo, {Joon Beom} and Oh, {Yeon Mok} and Lee, {Sang Do}",
year = "2010",
month = "4",
day = "1",
doi = "10.1016/j.rmed.2009.10.024",
language = "English",
volume = "104",
pages = "542--549",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype

AU - Lee, Ji Hyun

AU - Lee, Young Kyung

AU - Kim, Eun Kyung

AU - Kim, Tae Hyung

AU - Huh, Jin Won

AU - Kim, Woo Jin

AU - Lee, Jin Hwa

AU - Lee, Sang Min

AU - Lee, Sang Yeub

AU - Lim, Seong Yong

AU - Shin, Tae Rim

AU - Yoon, Ho Il

AU - Sheen, Seung Soo

AU - Kim, Nam Kug

AU - Seo, Joon Beom

AU - Oh, Yeon Mok

AU - Lee, Sang Do

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Rationale: Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disorder in which a number of different pathological processes lead to recognition of patient subgroups that may have individual characteristics and distinct responses to treatment. Objectives: We tested the hypothesis that responses of lung function to 3 months of combined inhalation of long-acting beta-agonist and corticosteroid might differ among patients with various COPD subtypes. Methods: We classified 165 COPD patients into four subtypes according to the severity of emphysema and airflow obstruction: emphysema-dominant, obstruction-dominant, mild-mixed, and severe-mixed. The emphysema-dominant subtype was defined by an emphysema index on computed tomography of more than 20% and FEV1 more than 45% of the predicted value. The obstruction-dominant subtype had an emphysema index ≤ 20% and FEV1 ≤ 45%, the mild-mixed subtype had an emphysema index ≤ 20% and FEV1 > 45%, and the severe-mixed subtype had an emphysema index > 20% and FEV1 ≤ 45%. Patients were recruited prospectively and treated with 3 months of combined inhalation of long-acting beta-agonist and corticosteroid. Results: After 3 months of combined inhalation of long-acting beta-agonist and corticosteroid, obstruction-dominant subtype patients showed a greater FEV1 increase and more marked dyspnea improvement than did the emphysema-dominant subgroup. The mixed-subtype patients (both subgroups) also showed significant improvement in FEV1 compared with the emphysema-dominant subgroup. Emphysema-dominant subtype patients showed no improvement in FEV1 or dyspnea after the 3-month treatment period. Conclusion: The responses to 3 months of combined inhalation of long-acting beta-agonist and corticosteroid differed according to COPD subtype.

AB - Rationale: Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disorder in which a number of different pathological processes lead to recognition of patient subgroups that may have individual characteristics and distinct responses to treatment. Objectives: We tested the hypothesis that responses of lung function to 3 months of combined inhalation of long-acting beta-agonist and corticosteroid might differ among patients with various COPD subtypes. Methods: We classified 165 COPD patients into four subtypes according to the severity of emphysema and airflow obstruction: emphysema-dominant, obstruction-dominant, mild-mixed, and severe-mixed. The emphysema-dominant subtype was defined by an emphysema index on computed tomography of more than 20% and FEV1 more than 45% of the predicted value. The obstruction-dominant subtype had an emphysema index ≤ 20% and FEV1 ≤ 45%, the mild-mixed subtype had an emphysema index ≤ 20% and FEV1 > 45%, and the severe-mixed subtype had an emphysema index > 20% and FEV1 ≤ 45%. Patients were recruited prospectively and treated with 3 months of combined inhalation of long-acting beta-agonist and corticosteroid. Results: After 3 months of combined inhalation of long-acting beta-agonist and corticosteroid, obstruction-dominant subtype patients showed a greater FEV1 increase and more marked dyspnea improvement than did the emphysema-dominant subgroup. The mixed-subtype patients (both subgroups) also showed significant improvement in FEV1 compared with the emphysema-dominant subgroup. Emphysema-dominant subtype patients showed no improvement in FEV1 or dyspnea after the 3-month treatment period. Conclusion: The responses to 3 months of combined inhalation of long-acting beta-agonist and corticosteroid differed according to COPD subtype.

KW - COPD

KW - Corticosteroid

KW - Inhaled long acting bronchodilator

KW - Subtype

UR - http://www.scopus.com/inward/record.url?scp=77649179376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649179376&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2009.10.024

DO - 10.1016/j.rmed.2009.10.024

M3 - Article

VL - 104

SP - 542

EP - 549

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 4

ER -